BioprintingMedicalProfessional Additive Manufacturing

International Stem Cell Corporation Presents New Liver Tissue Bioprinter

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

International Stem Cell Corporation, a California-based clinical stage biotechnology company, has developed a 3D bioprinter which utilizes proprietary liver progenitor cells (LPC), which differentiate into cholangiocytes, hepatocytes and stellate cells. For this type of liver tissue bioprinter, once 3D liver-like structures are produced from the LPC, they are expected to provide a treatment for various liver diseases once transplanted into the damaged liver. The LPC can be derived from any kind of pluripotent stem cells, including human embryonic, induced pluripotent, or parthenogenetic stem cells, via ISCO’s proprietary highly efficient and scalable differentiation method.

“I’m excited to announce that we have developed a new efficient technology to produce 3D liver tissue, which may be able to replace damaged tissue to restore liver functions. Additionally, the developed liver tissue  potentially can be used not only in liver treatment, but also in drug discovery as a model for drug screening, which opens up a potential multi-billion market for ISCO” commented Russell Kern, PhD., Executive Vice President and Chief Scientific Officer of ISCO. “We have already developed a master cell bank of the liver progenitor cells and, we are proceeding to test safety and efficacy of the cells in various models of liver diseases like liver cirrhosis and fibrosis” he continued.

The Liver (Gall Bladder Removed)

According to the American Liver Foundation, approximately 17,000 patients are on the U.S. liver transplant waiting list with only 6,000 liver transplants performed each year. Currently, there are no alternatives available for patients in need of a liver transplant other than to join the waiting list. Cirrhosis is the end stage in patients who have chronic progressive liver disease. While liver transplantation is a viable treatment option for these candidates, increasing waiting times for organ transplantation has led to the deaths of nearly 17% of those who were on the waiting list.

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of human pluripotent stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

3D Printing Media Network

3D Printing Media Network is the online trade media portal published by 3dpbm, a leading marketing and market research firm specializing in the AM industry. 3dpbm also publishes the 3D Printing Business Directory, the AM Focus eBook series and the 3dpbm Research AM Market Reports. 3D Printing Media Network was founded with the goal to provide the latest industry news, insights and opinions to a global audience of professionals and decision makers.
Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!